---
title: "Morning Trend | HAIXI PHARMA sees capital outflow, short-term adjustment pressure increases"
description: "HAIXI PHARMA (2637.HK) experienced significant capital outflow throughout the day yesterday, putting pressure on its stock price to decline. Competition in the innovative drug industry continues to in"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/270968818.md"
published_at: "2025-12-30T01:00:00.000Z"
---

# Morning Trend | HAIXI PHARMA sees capital outflow, short-term adjustment pressure increases

> HAIXI PHARMA (2637.HK) experienced significant capital outflow throughout the day yesterday, putting pressure on its stock price to decline. Competition in the innovative drug industry continues to intensify, with large pharmaceutical companies recently launching competing products in bulk, leading to a growing wait-and-see atmosphere in the market, short-term capital withdrawal, and increased sector differentiation. The main line of pharmaceutical growth has recently faced capital avoidance, with investors shifting their preference towards companies benefiting from performance recovery and policy support. Technically, the trend has weakened, with key short-term moving averages being breached multiple times. Trading volume has shrunk to low levels, indicating a lack of bullish sentiment in the market and an enhanced effect of capital outflow. If the market breaks below important support lines, it will further intensify the pressure for major players to exit. Market attention is shifting towards whether the bidding for innovative drugs, adjustments to the medical insurance catalog, and related policies will drive industry recovery. Operational risks are increasing, and sector rotation makes weak stocks more susceptible to being abandoned. It is recommended that short-term investors closely monitor policy dynamics and industry news, grasp the direction of capital flow, and if sector-driven sentiment does not recover, continue to avoid the risks of chasing highs and cutting losses. Fine control of positions and flexible adjustment operations have become essential strategies to cope with fluctuations in the innovative drug sector recently

HAIXI PHARMA (2637.HK) experienced significant capital outflow throughout the day yesterday, putting pressure on its stock price to decline. The competition in the innovative drug industry continues to intensify, with recent large pharmaceutical companies launching competing products in bulk, leading to a growing wait-and-see atmosphere in the market, short-term funds withdrawing, and increased sector differentiation. The main line of pharmaceutical growth has recently faced capital avoidance, with investors shifting their preference towards companies benefiting from performance recovery and policy support.

From a technical perspective, the segment trend has weakened, with key short-term moving averages being breached multiple times. Trading volume has shrunk to low levels, indicating a lack of market enthusiasm for buying, and the effect of capital outflow has intensified. If the market breaks through important support lines in the future, it will further exacerbate the pressure for major players to exit. Market attention is shifting towards whether the bidding for innovative drugs, adjustments to the medical insurance catalog, and related policies will drive industry recovery.

Operational risks are increasing, and sector rotation makes weak stocks more susceptible to being abandoned. It is recommended that short-term investors closely monitor policy dynamics and industry news, grasp the direction of capital flow, and if the sector-driven sentiment does not recover, continue to avoid the risks of chasing highs and cutting losses. Fine control of positions and flexible adjustment operations have become essential strategies to cope with the volatility in the innovative drug sector recently

### Related Stocks

- [02637.HK - HAIXI PHARMA](https://longbridge.com/en/quote/02637.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Guotai Haitong Remains a Buy on Zai Lab Ltd (1ZLB) | Guotai Haitong analyst maintained a Buy rating on Zai Lab Ltd yesterday and set a price target of HK$27.94.Claim 50% Off | [Link](https://longbridge.com/en/news/277338249.md) |
| Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | [Link](https://longbridge.com/en/news/276886600.md) |
| Suzhou Ribo Life Science's Cholesterol Medicine to Begin Phase 3 Trial | Suzhou Ribo Life Science's Cholesterol Medicine to Begin Phase 3 Trial | [Link](https://longbridge.com/en/news/277401406.md) |
| Forget Regencell Bioscience: This blue chip drug maker is the boring compounder you need | Don't follow general market sentiment when it comes to these two stocks. | [Link](https://longbridge.com/en/news/277366138.md) |
| Chinese robotaxi firms halt Dubai operations amid Middle East conflict | Chinese robotaxi firms Baidu's Apollo Go and WeRide have suspended operations in Dubai due to escalating geopolitical te | [Link](https://longbridge.com/en/news/277352074.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.